A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers

Inclusion Criteria: * Healthy male or female volunteers, 18 to 64 years of age, inclusive * Body mass index (BMI) 18 to 32 kg/m2 * Women of child-bearing potential and their partners must be willing to use two highly effective forms of contraception, one of which must be a barrier method, for the entire duration of the study (through study discharge) or for up to five half-lives after the last dose * Male subjects with female partners of child-bearing potential must be willing to use a condom during sexual activity for the duration of the study (through study discharge) or for up to five half-lives after the last dose Exclusion Criteria: * Pregnant or lactating women * Positive test for drugs of abuse (including ethanol) as per local standards * Willing to comply with a non-smoking policy during the in-clinic part of the study (Day -1 until discharge on Day 4) * Positive for hepatitis B, hepatitis C or HIV infection * History or presence of clinically significant disease or condition * Participation in an investigational drug or device study within 60 days prior to dosing * Current (or previous history of) exposure to therapeutic or investigational monoclonal antibody or chimeric biomolecule * Any confirmed clinically significant previous allergic drug reaction, or history of anaphylaxis